Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 26Lymphoma, Follicular 12Waldenstrom Macroglobulinemia 7Lymphoma, B-Cell, Marginal Zone 7Lymphoma, Non-Hodgkin 5Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 3Lymphoma 3Leukemia 3Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Large B-Cell, Diffuse 1Lymphoid Malignancies 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Hematologic Diseases 1Disease 1Carcinoma, Non-Small-Cell Lung 1B-cell Malignancies 1

Interventions

zanubrutinib 2tirabrutinib 1obinutuzumab 1idelalisib 1Voriconazole 1Fluconazole 1Diltiazem 1Clarithromycin 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × B-cell Malignancies × idelalisib × Clear all
NCT02457598 2025-06-17

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Gilead Sciences

Phase 1 Terminated
203 enrolled 43 charts
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡